Abstract
This phase II clinical trial was conducted in a series of patients with advanced breast cancer, refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of cisplatin 100 mg/m2, given as a 24-hr infusion on day 1 and vindesine (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in patients with poor bone marrow reserved (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluated patients, there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. Renal function impairment and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated patients warrants further evaluation of this regimen at an earlier stage of the disease.
| Original language | English |
|---|---|
| Pages (from-to) | 595-599 |
| Number of pages | 5 |
| Journal | European Journal of Cancer and Clinical Oncology |
| Volume | 21 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Cisplatin plus vindesine in advanced breast cancer : A phase II trial of the EORTC breast cancer cooperative group. / Paridaens, R.; Clarysse, A.; Rozencweig, M.; Rotmensz, N.; Heuson, J. C.
In: European Journal of Cancer and Clinical Oncology, Vol. 21, No. 5, 1985, p. 595-599.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cisplatin plus vindesine in advanced breast cancer
T2 - A phase II trial of the EORTC breast cancer cooperative group
AU - Paridaens, R.
AU - Clarysse, A.
AU - Rozencweig, M.
AU - Rotmensz, N.
AU - Heuson, J. C.
PY - 1985
Y1 - 1985
N2 - This phase II clinical trial was conducted in a series of patients with advanced breast cancer, refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of cisplatin 100 mg/m2, given as a 24-hr infusion on day 1 and vindesine (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in patients with poor bone marrow reserved (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluated patients, there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. Renal function impairment and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated patients warrants further evaluation of this regimen at an earlier stage of the disease.
AB - This phase II clinical trial was conducted in a series of patients with advanced breast cancer, refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of cisplatin 100 mg/m2, given as a 24-hr infusion on day 1 and vindesine (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in patients with poor bone marrow reserved (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluated patients, there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. Renal function impairment and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated patients warrants further evaluation of this regimen at an earlier stage of the disease.
UR - http://www.scopus.com/inward/record.url?scp=84886639312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886639312&partnerID=8YFLogxK
U2 - 10.1016/0197-0186(85)90116-0
DO - 10.1016/0197-0186(85)90116-0
M3 - Article
C2 - 4040025
AN - SCOPUS:84886639312
VL - 21
SP - 595
EP - 599
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 5
ER -